Carlos Alfonso, MD
Interventional Cardiology · Miami, FLNPI 1053562470
Payments from drug & device makers
Across 457 payments — averaging $222.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endotronix, Inc.$33K
- Inari Medical, Inc.$23K
- Boston Scientific$13K
- Medtronic$8K
- Abiomed$8K
- Merit Medical Systems Inc$4K
- plus $13K from 23 others
What the payments were for
- Consulting fees$4,0008%
- Speaking & faculty fees$18,35038%
- Travel & lodging$3,8028%
- Food & beverage$22,15146%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endotronix, Inc. | 3 | $32,843 |
| Inari Medical, Inc. | 47 | $23,045 |
| Boston Scientific | 53 | $12,526 |
| Medtronic(2 entities) | 179 | $8,443 |
| Abiomed | 16 | $7,586 |
| Merit Medical Systems Inc | 1 | $4,000 |
| Abbott | 73 | $3,994 |
| Shockwave Medical, Inc | 12 | $3,931 |
| Penumbra, Inc. | 9 | $1,117 |
| Ancora Heart, Inc. | 3 | $1,079 |
| Angiodynamics, Inc. | 10 | $739 |
| ZOLL Circulation Inc | 5 | $472 |
| Kestra Medical Technology Services, Inc. | 7 | $377 |
| Teleflex LLC | 4 | $326 |
| Edwards Lifesciences | 3 | $243 |
| Vifor Pharma, Inc. | 1 | $200 |
| Cleerly, Inc. | 8 | $187 |
| Lexicon Pharmaceuticals, Inc. | 2 | $148 |
| Livanova USA, Inc. | 4 | $125 |
| Biotronik Inc. | 1 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| BD | 2 | $52 |
| W. L. Gore & Associates, Inc. | 2 | $47 |
| Asahi Intecc USA, Inc. | 3 | $28 |
| Biosense Webster, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$9,000
- Impella$6,987
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,702
- CT THROMBECTOMY SYSTEM KIT$1,362
- FLOWTRIEVER CATHETER, S$1,362
- AccuCinch$1,079
- SYMPLICITY G3$863
- AVVIGO Guidance System$810
- Indigo System$726
- COREVALVE EVOLUT R$594
- ONYX FRONTIER$525
- AMPLATZER AMULET$426
- Resolute$416
- CROSSBOSS$304
- TherOx DS2 Console$288
- Catheter$288
- Downstream Cartridge$288
- RESOLUTE ONYX$285
- AlphaVac$272
- STINGRAY$265
How this compares
$101,774 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 99 | $97,282 |
| EliquisApixaban | 70 | $53,384 |
| JardianceEmpagliflozin | 43 | $41,996 |
| Repatha SureclickEvolocumab | 27 | $22,295 |
| XareltoRivaroxaban | 12 | $15,595 |
| VascepaIcosapent Ethyl | 20 | $6,854 |
| Ranolazine ErRanolazine | 47 | $5,359 |
| ClopidogrelClopidogrel Bisulfate | 212 | $2,239 |
| Atorvastatin Calcium | 202 | $1,679 |
| Rosuvastatin Calcium | 97 | $1,516 |
| Metoprolol Succinate | 149 | $1,097 |
| Ezetimibe | 66 | $1,058 |
| Nitroglycerin | 41 | $840 |
| Losartan Potassium | 80 | $759 |
| Carvedilol | 61 | $657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $53,38470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Pedro Martinez-ClarkMiami$1.7M
- Rimsky DenisMiami$1.2M
- Eduardo de MarchenaMiami$978K
- Ramon QuesadaMiami$593K
- Mauricio CohenMiami$351K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.